Institute of Hereditary Metabolic Diseases
Therapies
An important aspect of our research is the use of individual therapies in patients with lysosomal storage diseases. An example is the treatment of patients with MPS with anti-inflammatory drugs, which are approved and used for juvenile rheumatoid arthritis, among other conditions.
Why do we use these existing medications? Very simply because: We have found that inflammation is present in various lysosomal storage diseases and anti-inflammatory drugs have positive effects on unerlying symptoms. In our individual treatment trials in Salzburg and other international centers, specific anti-inflammatory drugs are used in close consideration of potential benefits and risks, in a personlized way using our developed decision-analysis framework tool...
Our approach is to establish individual therapies tailored to the needs of our patients. Patients with lysosomal storage diseases are highly heterogeneous, meaning unique also regarding the efficacy and safety of a medication. We can find out which treatment method suits best. A foundation for this has already been laid for patients with Mucopolysaccharidoses (MPS).
If you or your child are interested in our personalized treatment approach, we are pleased to be conatcted by you. Contact